NSE
Indoco Remedies LimitedINDOCO
Indoco Remedies Limited is a leading Indian pharmaceutical company that develops, manufactures, and markets generic medicines and vaccines. The company has received approval from the US FDA for its Lacosamide oral solution.
| Key products | Lacosamide oral solution, generic medicines and vaccines |
|---|---|
| Geography | India, USA |
| Competitors | Cipla Ltd, Sun Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd |
AI-generated overview — verify before relying on it.
Net institutional flow
+₹13.5 Cr
Institutional buyers
1 in / 0 out
High-impact filings
0 · tilt Neutral
Next corporate action
—
| # | Company | Inst. flow ₹Cr | Deals | Hi-impact | Filing mom. | Buzz | News |
|---|---|---|---|---|---|---|---|
| 1 | INDOCOThis | +₹13.5 Cr | 3 | — | — | +3 | 6 |
| 2 | ATALREAL | +₹2.9 Cr | 96 | — | — | — | — |
| 3 | MOBIKWIK | +₹0 Cr | 12 | — | — | — | — |
| 4 | QUADFUTURE | +₹0 Cr | 34 | — | — | — | — |
| 5 | IRMENERGY | — | — | — | — | — | — |
| 6 | MTNL | — | — | — | — | — | — |
| 7 | GATECH | — | — | — | — | — | — |
Ranked by net institutional flow (buys − sells, ₹Cr). Filing momentum = bullish − bearish filings; Buzz = news+social sentiment. Curate peers in the company admin.
- 2026-06-11BulkBUY · ₹13.2 CrNK SECURITIES RESEARCH PRIVATE LIMITED
- 2026-06-11BulkSELL · ₹13.2 CrNK SECURITIES RESEARCH PRIVATE LIMITED
- 2026-06-11FilingIndoco Remedies Limited has informed the Exchange about the Notice for transfer of equity shares of the CompanInvestor Call
- 2026-06-11NetDay net −₹0 Cr
- 2026-05-27BulkBUY · ₹13.5 CrICICI PRUDENTIAL MUTUAL FUND
- 2026-05-27NetDay net +₹13.5 Cr
- 2026-05-08NewsIndoco Remedies FY26 Results: Q4 Standalone Revenue Surges 26%, Newspaper Publication Confirmedscanx.trade
- 2026-02-24NewsIndoco Remedies Ltd stock jumps after major nod from US Food and Drug Administration—investors rush inIndiablooms
- 2026-01-30NewsIndoco Remedies Shares Soar 7% on Securing USFDA Final ApprovalEquitypandit
- 2026-01-30NewsIndoco Remedies shares gain over 8.5% post USFDA approval for Lacosamide oral solutionCNBC TV18
- 2025-11-06NewsIndoco Remedies Q2FY26 Revenue Up, Net Loss at ₹921 LakhHDFC Sky
- 2025-09-05NewsHere's Why Shareholders Should Examine Indoco Remedies Limited's (NSE:INDOCO) CEO Compensation Package More Clsimplywall.st
Merged from deals, filings, corporate actions and news — newest first. Compact rolls each day up to net flow + counts. Scope with the range above.
Filings that matter
- 2Investor CallNeutral
the Notice for transfer of equity shares of the Company to the Investor Education and Protection Fund ("IEPF")
Source PDF →
Institutional flow (weekly net)
3 deals · 2026-05-27 → 2026-06-11
| Date | Counterparty | Type | Side | Value |
|---|---|---|---|---|
| 2026-06-11 | NK SECURITIES RESEARCH PRIVATE LIMITED | Prop / churn | BUY | ₹13.2 Cr |
| 2026-06-11 | NK SECURITIES RESEARCH PRIVATE LIMITED | Prop / churn | SELL | ₹13.2 Cr |
| 2026-05-27 | ICICI PRUDENTIAL MUTUAL FUND | Institution | BUY | ₹13.5 Cr |
3 deals in the selected window — corporate actions are scoped to the same period. ~2 years of history available.
Results & transcripts
Financial results
None yet.
News & chatter on INDOCO
RSS News
6▲scanx.trade · 8/5/2026
▲Indiablooms · 24/2/2026
▲Equitypandit · 30/1/2026
▲CNBC TV18 · 30/1/2026
▼HDFC Sky · 6/11/2025
Google News RSS — links open the source.
Investdesk
0No articles yet.
Our coverage.
No Reddit chatter.
r/ posts mentioning the company.
Twitter / X
0No posts.
Posts mentioning the company.